We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC
Product News

Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC

Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC
Product News

Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Approximately 3 to 5 percent of NSCLC tumors have a rearrangement of the ALK gene, which can lead to impaired programmed cell death and abnormal cell growth. Using the new ALK Break Apart FISH Probe Kit, Response Genetics can detect rearrangements of the ALK gene on the 2p23 chromosome in tumors. The ALK Break Apart FISH Probe Kit is the only available diagnostic assay clinically validated to predict response to the targeted therapy XALKORI®.

“Diagnostics are playing an increasingly important role in cancer care by providing physicians with the information they need to determine the safest and most effective treatment for each patient,” said Denise McNairn, Interim CEO of Response Genetics. “Through the development of our leading edge ResponseDX™ genetic test panels, we have a proven track record in advancing patient care. And now, with the addition of FISH-based ALK testing capabilities, we are even better positioned to provide valuable clinical information, thus helping reduce the impact of diseases such as NSCLC on patients’ lives.”

Advertisement